Background
Flavivirus infections, TBEV, tick-borne encephalitis, YFV, yellow fever
VIRUS, JAPANESE ENCEPHALITIS, TICK-BORNE ENCEPHALITIS, YELLOW FEVER, FLAVIVIRUS INFECTION
The authors have declared that no competing interests exist.‡ These authors are joint senior authors on this work.Flavivirus infections pose a significant global health burden underscoring the need for the development of safe and effective vaccination strategies. Available flavivirus vaccines are from time to time concomitantly delivered to individuals. Co-administration of different vaccines saves time and visits to health care units and vaccine clinics. It serves to provide protection against multiple pathogens in a shorter time-span; e.g., for individuals travelling to different endemic areas. However, safety and immunogenicity-related responses have not been appropriately evaluated upon concomitant delivery of these vaccines. Therefore, we performed an open label, non-randomized clinical trial studying the safety and immunogenicity following concomitant delivery of the yellow fever virus (YFV) vaccine with tick-borne encephalitis virus (TBEV) and Japanese encephalitis virus (JE) virus vaccines.